Accurate diagnosis of traumatic brain injury (TBI) is critical to effective management and intervention, but can be challenging in patients with mild TBI. A substantial number of studies have reported the use of circulating biomarkers as signatures for TBI, capable of improving diagnostic accuracy and clinical decision-making beyond current practice standards. We performed a systematic review and meta-analysis to comprehensively and critically evaluate the existing body of evidence for the use of blood protein biomarkers (S100B, GFAP, NSE, UCH-L1, Tau and Neurofilament proteins) for diagnosis of intracranial lesions on CT following mild TBI. Effects of potential confounding factors and differential diagnostic performance of the included markers were explored. Furthermore, appropriateness of study design, analysis, quality and demonstration of clinical utility were assessed. Studies published up to October 2016 were identified through a MEDLINE, EMBASE and CINHAL search. Following screening of the identified articles, 26 were selected as relevant. We found that measurement of S100B can help informed decision making in the emergency department possibly reducing resource use, but there is insufficient evidence that any of the other markers is ready for clinical application. Our work pointed out serious problems in the design, analysis and reporting of many of the studies and identified a substantial heterogeneity and research gaps. These findings emphasize the importance of methodologically rigorous studies focused on a biomarker's intended use and defining standardized, validated and reproducible approaches. The living nature of this systematic review, which will summarize key updated information as it becomes available, can inform and guide future implementation of biomarkers in the clinical arena.

Blood-Based Protein Biomarkers for the Management of Traumatic Brain Injuries in Adults Presenting to Emergency Departments with Mild Brain Injury: A Living Systematic Review and Meta-Analysis

Mondello, Stefania
Primo
Writing – Original Draft Preparation
;
2018-01-01

Abstract

Accurate diagnosis of traumatic brain injury (TBI) is critical to effective management and intervention, but can be challenging in patients with mild TBI. A substantial number of studies have reported the use of circulating biomarkers as signatures for TBI, capable of improving diagnostic accuracy and clinical decision-making beyond current practice standards. We performed a systematic review and meta-analysis to comprehensively and critically evaluate the existing body of evidence for the use of blood protein biomarkers (S100B, GFAP, NSE, UCH-L1, Tau and Neurofilament proteins) for diagnosis of intracranial lesions on CT following mild TBI. Effects of potential confounding factors and differential diagnostic performance of the included markers were explored. Furthermore, appropriateness of study design, analysis, quality and demonstration of clinical utility were assessed. Studies published up to October 2016 were identified through a MEDLINE, EMBASE and CINHAL search. Following screening of the identified articles, 26 were selected as relevant. We found that measurement of S100B can help informed decision making in the emergency department possibly reducing resource use, but there is insufficient evidence that any of the other markers is ready for clinical application. Our work pointed out serious problems in the design, analysis and reporting of many of the studies and identified a substantial heterogeneity and research gaps. These findings emphasize the importance of methodologically rigorous studies focused on a biomarker's intended use and defining standardized, validated and reproducible approaches. The living nature of this systematic review, which will summarize key updated information as it becomes available, can inform and guide future implementation of biomarkers in the clinical arena.
File in questo prodotto:
File Dimensione Formato  
2018 JNT.pdf

accesso aperto

Descrizione: Articolo principale - First online (2018)
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 992.28 kB
Formato Adobe PDF
992.28 kB Adobe PDF Visualizza/Apri
2021 - Blood-Based Protein Biomarkers for the Management.pdf

accesso aperto

Descrizione: Articolo principale - Edizione definitiva (2021)
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 993.75 kB
Formato Adobe PDF
993.75 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3120445
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 88
social impact